SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

February 27, 2015 08:00 ET

CymaBay to Present at Upcoming Investor Conferences

NEWARK, CA--(Marketwired - February 27, 2015) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that members of its senior management team are scheduled to present at three upcoming investor conferences detailed below.

Cowen and Company 35th Annual Health Care Conference
Boston Marriott Copley Place Hotel, Boston, MA
Wednesday, March 4
10:00 - 10:30 a.m. EST

27th Annual ROTH Conference
The Ritz-Carlton, Laguna Niguel, CA
Tuesday, March 10
1:00 - 1:30 p.m. PST

BioCentury 22nd Annual Future Leaders In The Biotech Industry
Millennium Broadway Hotel & Conference Center, New York, NY
Friday, March 20
9:00 - 9:25 a.m. EST

The Cowen and Company and ROTH presentations will be webcast live and available for replay for up to 30 days at

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay is in the process of initiating a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit

Contact Information

  • Contact:

    Sujal Shah 
    CymaBay Therapeutics, Inc. 
    (510) 293-8800